Tag: Cancer: Prostate
Ultrasound Ablation Offers Option for Some With Prostate Cancer
Bilateral prostate cancer at diagnosis was sole predictor of Grade Group 2 or greater recurrence
Darolutamide Boosts Survival in Nonmetastatic Prostate Cancer
Risk for death significantly lower versus placebo in nonmetastatic, castration-resistant prostate cancer
Factors Clarify Racial Disparity in Prostate Cancer Survival
Education, median household income, and insurance status contribute most to racial disparity in the U.S.
Delayed Radiotherapy Not Tied to Worse Survival in Prostate Cancer
Initiation of RT up to six months after androgen deprivation therapy not tied to worse overall survival
Guidance Issued for Genetic Testing in Prostate Cancer
Germline testing advised for metastatic disease, family history suggestive of hereditary disease
Delayed Radiotherapy Not Tied to Worse Survival in Prostate Cancer
Initiation of RT up to six months after androgen deprivation therapy not tied to worse overall survival
Prostate Cancer Trial Participants Overwhelmingly White
Since 1990, proportion of white participants in prostate cancer clinical trials has remained >80 percent
ASCO: Relugolix Superior to Leuprolide in Advanced Prostate Cancer
And, enzalutamide improves median overall survival in nonmetastatic, castration-resistant prostate cancer
Local-Stage Prostate Cancer Incidence Rates Continue to Drop
Rates of regional- and distant-stage prostate cancer increasing in the U.S. among men aged ≥50 years
Risk for SARS-CoV-2 Lower for Prostate Cancer Patients on ADT
Risk reduced fourfold with androgen-deprivation therapy versus other treatment for prostate cancer
